Statistical modelling for life sciences

IN COLLABORATION WITH: Centre de Mathématiques Appliquées (CMAP)

DOMAIN
Digital Health, Biology and Earth

THEME
Modeling and Control for Life Sciences
# Contents

<table>
<thead>
<tr>
<th>Project-Team XPOP</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Team members, visitors, external collaborators</td>
<td>2</td>
</tr>
<tr>
<td>2 Overall objectives</td>
<td>2</td>
</tr>
<tr>
<td>2.1 Developing sound, useful and usable methods</td>
<td>2</td>
</tr>
<tr>
<td>2.2 Combining numerical, statistical and stochastic components of a model</td>
<td>2</td>
</tr>
<tr>
<td>2.3 Developing future standards</td>
<td>3</td>
</tr>
<tr>
<td>3 Research program</td>
<td>3</td>
</tr>
<tr>
<td>3.1 Scientific positioning</td>
<td>3</td>
</tr>
<tr>
<td>3.2 The mixed-effects models</td>
<td>4</td>
</tr>
<tr>
<td>3.3 Computational Statistical Methods</td>
<td>4</td>
</tr>
<tr>
<td>3.4 Markov Chain Monte Carlo algorithms</td>
<td>5</td>
</tr>
<tr>
<td>3.5 Parameter estimation</td>
<td>5</td>
</tr>
<tr>
<td>3.6 Model building</td>
<td>6</td>
</tr>
<tr>
<td>3.7 Model evaluation</td>
<td>7</td>
</tr>
<tr>
<td>3.8 Missing data</td>
<td>7</td>
</tr>
<tr>
<td>4 Application domains</td>
<td>8</td>
</tr>
<tr>
<td>4.1 Management of severe trauma</td>
<td>8</td>
</tr>
<tr>
<td>4.2 Precision medicine and pharmacogenomics</td>
<td>8</td>
</tr>
<tr>
<td>4.3 Oncology</td>
<td>9</td>
</tr>
<tr>
<td>4.4 Anesthesiology</td>
<td>9</td>
</tr>
<tr>
<td>4.5 Intracellular processes</td>
<td>10</td>
</tr>
<tr>
<td>4.6 Population pharmacometrics</td>
<td>10</td>
</tr>
<tr>
<td>4.7 Mass spectrometry</td>
<td>11</td>
</tr>
<tr>
<td>5 Highlights of the year</td>
<td>11</td>
</tr>
<tr>
<td>5.1 Awards</td>
<td>11</td>
</tr>
<tr>
<td>5.2 Other</td>
<td>12</td>
</tr>
<tr>
<td>6 New software and platforms</td>
<td>12</td>
</tr>
<tr>
<td>6.1 New software</td>
<td>12</td>
</tr>
<tr>
<td>6.1.1 mlxR</td>
<td>12</td>
</tr>
<tr>
<td>6.1.2 Rsmlx</td>
<td>12</td>
</tr>
<tr>
<td>6.1.3 SPIX</td>
<td>12</td>
</tr>
<tr>
<td>7 New results</td>
<td>13</td>
</tr>
<tr>
<td>7.1 Fast incremental expectation-maximization algorithm</td>
<td>13</td>
</tr>
<tr>
<td>7.2 A mathematical approach to deal with nanoparticle polydispersity in surface enhanced Raman spectroscopy to quantify antineoplastic agents</td>
<td>13</td>
</tr>
<tr>
<td>7.3 Doubly robust treatment effect estimation with missing attributes</td>
<td>13</td>
</tr>
<tr>
<td>7.4 Imputation and low-rank estimation with Missing Non At Random data</td>
<td>13</td>
</tr>
<tr>
<td>7.5 On Stability of a Class of Filters for Nonlinear Stochastic Systems</td>
<td>14</td>
</tr>
<tr>
<td>7.6 SPIX: a new software package to reveal chemical reactions at trace amounts in very complex mixtures from high-resolution mass spectra data sets</td>
<td>14</td>
</tr>
<tr>
<td>8 Partnerships and cooperations</td>
<td>14</td>
</tr>
<tr>
<td>8.1 National initiatives</td>
<td>14</td>
</tr>
<tr>
<td>8.1.1 ANR</td>
<td>14</td>
</tr>
<tr>
<td>8.1.2 Institut National du Cancer (INCa)</td>
<td>14</td>
</tr>
</tbody>
</table>
9 Dissemination 15
9.1 Promoting scientific activities 15
9.1.1 Journal 15
9.1.2 Leadership within the scientific community 15
9.1.3 Scientific expertise 15
9.1.4 Research administration 15
9.2 Teaching - Supervision - Juries 15
9.2.1 Teaching 15
9.2.2 Supervision 16
9.3 Popularization 16
9.3.1 Education 16
9.3.2 Interventions 16

10 Scientific production 16
10.1 Major publications 16
10.2 Publications of the year 16
Project-Team XPOP

Creation of the Team: 2016 January 01, updated into Project-Team: 2017 July 01

Keywords

Computer sciences and digital sciences

A3.1.1. – Modeling, representation
A3.2.3. – Inference
A3.3. – Data and knowledge analysis
A3.3.1. – On-line analytical processing
A3.3.2. – Data mining
A3.3.3. – Big data analysis
A3.4.1. – Supervised learning
A3.4.2. – Unsupervised learning
A3.4.4. – Optimization and learning
A3.4.5. – Bayesian methods
A3.4.6. – Neural networks
A3.4.7. – Kernel methods
A3.4.8. – Deep learning
A5.9.2. – Estimation, modeling
A6.1.1. – Continuous Modeling (PDE, ODE)
A6.1.2. – Stochastic Modeling
A6.2.2. – Numerical probability
A6.2.3. – Probabilistic methods
A6.2.4. – Statistical methods
A6.3.3. – Data processing
A6.3.5. – Uncertainty Quantification

Other research topics and application domains

B1.1.4. – Genetics and genomics
B1.1.7. – Bioinformatics
B1.1.10. – Systems and synthetic biology
B2.2.3. – Cancer
B2.2.4. – Infectious diseases, Virology
B2.3. – Epidemiology
B2.4.1. – Pharmacokinetics and dynamics
B9.1.1. – E-learning, MOOC
1 Team members, visitors, external collaborators

Research Scientists
- Marc Lavielle [Team leader, Inria, Senior Researcher]
- Erwan Le Pennec [École polytechnique, Researcher]

Faculty Members
- Julie Josse [École polytechnique, Associate Professor, until Aug 2020, HDR]
- Eric Moulines [École polytechnique, Professor, HDR]

Post-Doctoral Fellow
- Angie Pineda Centeno [École polytechnique]

PhD Students
- Wei Jiang [École polytechnique, until Sep 2020]
- Pablo Jimenez [Institut Polytechnique de Paris]
- Achille Thin [École polytechnique]
- Marine Zulian [Dassault Systèmes, until Feb 2020]

Administrative Assistant
- Hanadi Dib [Inria]

2 Overall objectives

2.1 Developing sound, useful and usable methods
The main objective of XPOP is to develop new sound and rigorous methods for statistical modeling in the field of biology and life sciences. These methods for modeling include statistical methods of estimation, model diagnostics, model building and model selection as well as methods for numerical models (systems of ordinary and partial differential equations). Historically, the key area where these methods have been used is population pharmacokinetics. However, the framework is currently being extended to sophisticated numerical models in the contexts of viral dynamics, glucose-insulin processes, tumor growth, precision medicine, spectrometry, intracellular processes, etc.

Furthermore, an important aim of XPOP is to transfer the methods developed into software packages so that they can be used in everyday practice.

2.2 Combining numerical, statistical and stochastic components of a model
Mathematical models that characterize complex biological phenomena are defined by systems of ordinary differential equations when dealing with dynamical systems that evolve with respect to time, or by partial differential equations when there is a spatial component in the model. Also, it is sometimes useful to integrate a stochastic aspect into the dynamical system in order to model stochastic intra-individual variability.

In order to use such methods, we must deal with complex numerical difficulties, generally related to resolving the systems of differential equations. Furthermore, to be able to check the quality of a model (i.e. its descriptive and predictive performances), we require data. The statistical aspect of the model is thus critical in how it takes into account different sources of variability and uncertainty, especially when
data come from several individuals and we are interested in characterizing the inter-subject variability. Here, the tools of reference are mixed-effects models.

Confronted with such complex modeling problems, one of the goals of XPOP is to show the importance of combining numerical, statistical and stochastic approaches.

### 2.3 Developing future standards

Linear mixed-effects models have been well-used in statistics for a long time. They are a classical approach, essentially relying on matrix calculations in Gaussian models. Whereas a solid theoretical base has been developed for such models, nonlinear mixed-effects models (NLMEM) have received much less attention in the statistics community, even though they have been applied to many domains of interest. It has thus been the users of these models, such as pharmacometricians, who have taken them and developed methods, without really looking to develop a clean theoretical framework or understand the mathematical properties of the methods. This is why a standard estimation method in NLMEM is to linearize the model, and few people have been interested in understanding the properties of estimators obtained in this way.

Statisticians and pharmacometricians frequently realize the need to create bridges between these two communities. We are entirely convinced that this requires the development of new standards for population modeling that can be widely accepted by these various communities. These standards include the language used for encoding a model, the approach for representing a model and the methods for using it:

- **The approach.** Our approach consists in seeing a model as hierarchical, represented by a joint probability distribution. This joint distribution can be decomposed into a product of conditional distributions, each associated with a submodel (model for observations, individual parameters, etc.). Tasks required of the modeler are thus related to these probability distributions.

- **The methods.** Many tests have shown that algorithms implemented in Monolix are the most reliable, all the while being extremely fast. In fact, these algorithms are precisely described and published in well known statistical journals. In particular, the SAEM algorithm, used for calculating the maximum likelihood estimation of population parameters, has shown its worth in numerous situations. Its mathematical convergence has also been proven under quite general hypotheses.

- **The language.** Mlxtran is used by Monolix and other modeling tools and is today by far the most advanced language for representing models. Initially developed for representing pharmacometric models, its syntax also allows it to easily code dynamical systems defined by a system of ODEs, and statistical models involving continuous, discrete and survival variables. This flexibility is a true advantage both for numerical modelers and statisticians.

### 3 Research program

#### 3.1 Scientific positioning

"Interfaces" is the defining characteristic of XPOP:

- **The interface between statistics, probability and numerical methods.** Mathematical modelling of complex biological phenomena require to combine numerical, stochastic and statistical approaches. The CMAP is therefore the right place to be for positioning the team at the interface between several mathematical disciplines.

- **The interface between mathematics and the life sciences.** The goal of XPOP is to bring the right answers to the right questions. These answers are mathematical tools (statistics, numerical methods, etc.), whereas the questions come from the life sciences (pharmacology, medicine, biology, etc.). This is why the point of XPOP is not to take part in mathematical projects only, but also pluridisciplinary ones.

- **The interface between mathematics and software development.** The development of new methods is the main activity of XPOP. However, new methods are only useful if they end up being implemented in a software tool. On one hand, a strong partnership with Lixoft (the spin-off company who continue
developing MONOLIX) allows us to maintaining this positioning. On the other hand, several members of the team are very active in the R community and develop widely used packages.

### 3.2 The mixed-effects models

Mixed-effects models are statistical models with both fixed effects and random effects. They are well-adapted to situations where repeated measurements are made on the same individual/statistical unit.

Consider first a single subject $i$ of the population. Let $y_i = (y_{ij}, 1 \leq j \leq n_i)$ be the vector of observations for this subject. The model that describes the observations $y_i$ is assumed to be a parametric probabilistic model: let $p_Y(y_i; \psi)$ be the probability distribution of $y_i$, where $\psi$ is a vector of parameters.

In a population framework, the vector of parameters $\psi_i$ is assumed to be drawn from a population distribution $p_{\psi}(\psi_i; \theta)$ where $\theta$ is a vector of population parameters.

Then, the probabilistic model is the joint probability distribution

$$p(y_i, \psi_i; \theta) = p_Y(y_i|\psi_i)p_{\psi}(\psi_i; \theta)$$

(1)

To define a model thus consists in defining precisely these two terms.

In most applications, the observed data $y_i$ are continuous longitudinal data. We then assume the following representation for $y_i$:

$$y_{ij} = f(t_{ij}, \psi_i) + g(t_{ij}, \psi_i)c_{ij} + \varepsilon_{ij}, 1 \leq i \leq N, 1 \leq j \leq n_i.$$  

(2)

Here, $y_{ij}$ is the observation obtained from subject $i$ at time $t_{ij}$. The residual errors ($\varepsilon_{ij}$) are assumed to be standardized random variables (mean zero and variance 1). The residual error model is represented by function $g$ in model (2).

Function $f$ is usually the solution to a system of ordinary differential equations (pharmacokinetic/pharmacodynamic models, etc.) or a system of partial differential equations (tumor growth, respiratory system, etc.). This component is a fundamental component of the model since it defines the prediction of the observed kinetics for a given set of parameters.

The vector of individual parameters $\psi_i$ is usually function of a vector of population parameters $\psi_{\text{pop}}$, a vector of random effects $\eta_i \sim \mathcal{N}(0, \Omega)$, a vector of individual covariates $c_i$ (weight, age, gender, . . . ) and some fixed effects $\beta$.

The joint model of $y$ and $\psi$ depends then on a vector of parameters $\theta = (\psi_{\text{pop}}, \beta, \Omega)$.

### 3.3 Computational Statistical Methods

Central to modern statistics is the use of probabilistic models. To relate these models to data requires the ability to calculate the probability of the observed data: the likelihood function, which is central to most statistical methods and provides a principled framework to handle uncertainty.

The emergence of computational statistics as a collection of powerful and general methodologies for carrying out likelihood-based inference made complex models with non-standard data accessible to likelihood, including hierarchical models, models with intricate latent structure, and missing data.

In particular, algorithms previously developed by POPIX for mixed effects models, and today implemented in several software tools (especially MONOLIX) are part of these methods:

- the adaptive Metropolis-Hastings algorithm allows one to sample from the conditional distribution of the individual parameters $p(\psi_i|y_i; c_i, \theta)$,
- the SAEM algorithm is used to maximize the observed likelihood $\mathcal{L}(\theta; y) = p(y; \theta)$,
- Importance Sampling Monte Carlo simulations provide an accurate estimation of the observed log-likelihood $\log(\mathcal{L}(\theta; y))$.

Computational statistics is an area which remains extremely active today. Recently, one can notice that the incentive for further improvements and innovation comes mainly from three broad directions: the high dimensional challenge, the quest for adaptive procedures that can eliminate the cumbersome process of tuning “by hand” the settings of the algorithms and the need for flexible theoretical support, arguably required by all recent developments as well as many of the traditional MCMC algorithms that are widely used in practice.

Working in these three directions is a clear objective for XPOP.
3.4 Markov Chain Monte Carlo algorithms

While these Monte Carlo algorithms have turned into standard tools over the past decade, they still face difficulties in handling less regular problems such as those involved in deriving inference for high-dimensional models. One of the main problems encountered when using MCMC in this challenging settings is that it is difficult to design a Markov chain that efficiently samples the state space of interest.

The Metropolis-adjusted Langevin algorithm (MALA) is a Markov chain Monte Carlo (MCMC) method for obtaining random samples from a probability distribution for which direct sampling is difficult. As the name suggests, MALA uses a combination of two mechanisms to generate the states of a random walk that has the target probability distribution as an invariant measure:

1. new states are proposed using Langevin dynamics, which use evaluations of the gradient of the target probability density function;
2. these proposals are accepted or rejected using the Metropolis-Hastings algorithm, which uses evaluations of the target probability density (but not its gradient).

Informally, the Langevin dynamics drives the random walk towards regions of high probability in the manner of a gradient flow, while the Metropolis-Hastings accept/reject mechanism improves the mixing and convergence properties of this random walk.

Several extensions of MALA have been proposed recently by several authors, including fMALA (fast MALA), AMALA (anisotropic MALA), MMALA (manifold MALA), position-dependent MALA (PMALA), …

MALA and these extensions have demonstrated to represent very efficient alternative for sampling from high dimensional distributions. We therefore need to adapt these methods to general mixed effects models.

3.5 Parameter estimation

The Stochastic Approximation Expectation Maximization (SAEM) algorithm has shown to be extremely efficient for maximum likelihood estimation in incomplete data models, and particularly in mixed effects models for estimating the population parameters. However, there are several practical situations for which extensions of SAEM are still needed:

**High dimensional model:** a complex physiological model may have a large number of parameters (in the order of 100). Then several problems arise:

- when most of these parameters are associated with random effects, the MCMC algorithm should be able to sample, for each of the \( N \) individuals, parameters from a high dimensional distribution. Efficient MCMC methods for high dimensions are then required.
- Practical identifiability of the model is not ensured with a limited amount of data. In other words, we cannot expect to be able to properly estimate all the parameters of the model, including the fixed effects and the variance-covariance matrix of the random effects. Then, some random effects should be removed, assuming that some parameters do not vary in the population. It may also be necessary to fix the value of some parameters (using values from the literature for instance). The strategy to decide which parameters should be fixed and which random effects should be removed remains totally empirical. XPOP aims to develop a procedure that will help the modeller to take such decisions.

**Large number of covariates:** the covariate model aims to explain part of the inter-patient variability of some parameters. Classical methods for covariate model building are based on comparisons with respect to some criteria, usually derived from the likelihood (AIC, BIC), or some statistical test (Wald test, LRT, etc.). In other words, the modelling procedure requires two steps: first, all possible models are fitted using some estimation procedure (e.g. the SAEM algorithm) and the likelihood of each model is computed using a numerical integration procedure (e.g. Monte Carlo Importance Sampling); then, a
model selection procedure chooses the “best” covariate model. Such a strategy is only possible with a reduced number of covariates, i.e., with a “small” number of models to fit and compare.

As an alternative, we are thinking about a Bayesian approach which consists of estimating simultaneously the covariate model and the parameters of the model in a single run. An (informative or uninformative) prior is defined for each model by defining a prior probability for each covariate to be included in the model. In other words, we extend the probabilistic model by introducing binary variables that indicate the presence or absence of each covariate in the model. Then, the model selection procedure consists of estimating and maximizing the conditional distribution of this sequence of binary variables. Furthermore, a probability can be associated to any of the possible covariate models.

This conditional distribution can be estimated using an MCMC procedure combined with the SAEM algorithm for estimating the population parameters of the model. In practice, such an approach can only deal with a limited number of covariates since the dimension of the probability space to explore increases exponentially with the number of covariates. Consequently, we would like to have methods able to find a small number of variables (from a large starting set) that influence certain parameters in populations of individuals. That means that, instead of estimating the conditional distribution of all the covariate models as described above, the algorithm should focus on the most likely ones.

**Fixed parameters:** it is quite frequent that some individual parameters of the model have no random component and are purely fixed effects. Then, the model may not belong to the exponential family anymore and the original version of SAEM cannot be used as it is. Several extensions exist:

- introduce random effects with decreasing variances for these parameters,
- introduce a prior distribution for these fixed effects,
- apply the stochastic approximation directly on the sequence of estimated parameters, instead of the sufficient statistics of the model.

None of these methods always work correctly. Furthermore, what are the pros and cons of these methods is not clear at all. Then, developing a robust methodology for such model is necessary.

**Convergence toward the global maximum of the likelihood:** convergence of SAEM can strongly depend on the initial guess when the observed likelihood has several local maxima. A kind of simulated annealing version of SAEM was previously developed and implemented in MONOLIX. The method works quite well in most situations but there is no theoretical justification and choosing the settings of this algorithm (i.e. how the temperature decreases during the iterations) remains empirical. A precise analysis of the algorithm could be very useful to better understand why it "works" in practice and how to optimize it.

**Convergence diagnostic:** Convergence of SAEM was theoretically demonstrated under very general hypothesis. Such result is important but of little interest in practice at the time to use SAEM in a finite amount of time, i.e. in a finite number of iterations. Some qualitative and quantitative criteria should be defined in order to both optimize the settings of the algorithm, detect a poor convergence of SAEM and evaluate the quality of the results in order to avoid using them unwisely.

### 3.6 Model building

Defining an optimal strategy for model building is far from easy because a model is the assembled product of numerous components that need to been evaluated and perhaps improved: the structural model, residual error model, covariate model, covariance model, etc.

How to proceed so as to obtain the best possible combination of these components? There is no magic recipe but an effort will be made to provide some qualitative and quantitative criteria in order to help the modeller for building his model.

The strategy to take will mainly depend on the time we can dedicate to building the model and the time required for running it. For relatively simple models for which parameter estimation is fast, it is
possible to fit many models and compare them. This can also be done if we have powerful computing facilities available (e.g., a cluster) allowing large numbers of simultaneous runs.

However, if we are working on a standard laptop or desktop computer, model building is a sequential process in which a new model is tested at each step. If the model is complex and requires significant computation time (e.g., when involving systems of ODEs), we are constrained to limit the number of models we can test in a reasonable time period. In this context, it also becomes important to carefully choose the tasks to run at each step.

### 3.7 Model evaluation

Diagnostic tools are recognized as an essential method for model assessment in the process of model building. Indeed, the modeler needs to confront "his" model with the experimental data before concluding that this model is able to reproduce the data and before using it for any purpose, such as prediction or simulation for instance.

The objective of a diagnostic tool is twofold: first we want to check if the assumptions made on the model are valid or not; then, if some assumptions are rejected, we want to get some guidance on how to improve the model.

As is the usual case in statistics, it is not because this "final" model has not been rejected that it is necessarily the "true" one. All that we can say is that the experimental data does not allow us to reject it. It is merely one of perhaps many models that cannot be rejected.

Model diagnostic tools are for the most part graphical, i.e., visual; we "see" when something is not right between a chosen model and the data it is hypothesized to describe. These diagnostic plots are usually based on the empirical Bayes estimates (EBEs) of the individual parameters and EBEs of the random effects: scatterplots of individual parameters versus covariates to detect some possible relationship, scatterplots of pairs of random effects to detect some possible correlation between random effects, plot of the empirical distribution of the random effects (boxplot, histogram,...) to check if they are normally distributed, ...

The use of EBEs for diagnostic plots and statistical tests is efficient with rich data, i.e. when a significant amount of information is available in the data for recovering accurately all the individual parameters. On the contrary, tests and plots can be misleading when the estimates of the individual parameters are greatly shrunk.

We propose to develop new approaches for diagnosing mixed effects models in a general context and derive formal and unbiased statistical tests for testing separately each feature of the model.

### 3.8 Missing data

The ability to easily collect and gather a large amount of data from different sources can be seen as an opportunity to better understand many processes. It has already led to breakthroughs in several application areas. However, due to the wide heterogeneity of measurements and objectives, these large databases often exhibit an extraordinary high number of missing values. Hence, in addition to scientific questions, such data also present some important methodological and technical challenges for data analyst.

Missing values occur for a variety of reasons: machines that fail, survey participants who do not answer certain questions, destroyed or lost data, dead animals, damaged plants, etc. Missing values are problematic since most statistical methods cannot be applied directly on an incomplete data. Many progress have been made to properly handle missing values. However, there are still many challenges that need to be addressed in the future, that are crucial for the users.

- State of arts methods often consider the case of continuous or categorical data whereas real data are very often mixed. The idea is to develop a multiple imputation method based on a specific principal component analysis (PCA) for mixed data. Indeed, PCA has been used with success to predict (impute) the missing values. A very appealing property is the ability of the method to handle very large matrices with large amount of missing entries.
- The asymptotic regime underlying modern data is not any more to consider that the sample size increases but that both number of observations and number of variables are very large. In practice
first experiments showed that the coverage properties of confidence areas based on the classical methods to estimate variance with missing values varied widely. The asymptotic method and the bootstrap do well in low-noise setting, but can fail when the noise level gets high or when the number of variables is much greater than the number of rows. On the other hand, the jackknife has good coverage properties for large noisy examples but requires a minimum number of variables to be stable enough.

- Inference with missing values is usually performed under the assumption of "Missing at Random" (MAR) values which means that the probability that a value is missing may depend on the observed data but does not depend on the missing value itself. In real data and in particular in data coming from clinical studies, both "Missing Non at Random" (MNAR) and MAR values occur. Taking into account in a proper way both types of missing values is extremely challenging but is worth investigating since the applications are extremely broad.

It is important to stress that missing data models are part of the general incomplete data models addressed by XPOP. Indeed, models with latent variables (i.e. non observed variables such as random effects in a mixed effects model), models with censored data (e.g. data below some limit of quantification) or models with dropout mechanism (e.g. when a subject in a clinical trial fails to continue in the study) can be seen as missing data models.

4 Application domains

4.1 Management of severe trauma

(joint project with the Traumabase group, AP-HP)

Major trauma is defined as any injury that endangers the life or the functional integrity of a person. It has been shown that management of major trauma based on standardized and protocol based care improves prognosis of patients especially for the two main causes of death in major trauma i.e., hemorrhage and traumatic brain injury.

However, evidence shows that patient management even in mature trauma systems often exceeds acceptable time frames, and despite existing guidelines deviations from protocol-based care are often observed. These deviations lead to a high variability in care and are associated with bad outcome such as inadequate hemorrhage control or delayed transfusion. Two main factors explain these observations. First, decision-making in trauma care is particularly demanding, because it requires rapid and complex decisions under time pressure in a very dynamic and multi-player environment characterized by high levels of uncertainty and stress. Second, being a complex and multi-player process, trauma care is affected by fragmentation. Fragmentation is often the result of loss or deformation of information.

This disruptive influence prevents providers to engage with each other and commit to the care process. In order to respond to this challenge, our program has set the ambitious goal to develop a trauma decision support tool, the TraumaMatrix. The program aims to provide an integrative decision support and information management solution to clinicians for the first 24 hours of major trauma management. This program is divided into three steps.

Based on a detailed and high quality trauma database, Step 1 consists in developing the mathematical tools and models to predict trauma specific outcomes and decisions. This step raises considerable scientific and methodological challenges.

Step 2 will use these methods to apply them to develop in close cooperation with trauma care experts the decision support tool and develop a user friendly and ergonomic interface to be used by clinicians.

Step 3 will further develop the tool and interface and test in real-time its impact on clinician decision making and patient outcome.

4.2 Precision medicine and pharmacogenomics

(joint project with Dassault Systèmes)

Pharmacogenomics involves using an individual's genome to determine whether or not a particular therapy, or dose of therapy, will be effective. Indeed, people's reaction to a given drug depends on their physiological state and environmental factors, but also to their individual genetic make-up.
Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. While some advances in precision medicine have been made, the practice is not currently in use for most diseases.

Currently, in the traditional population approach, inter-individual variability in the reaction to drugs is modeled using covariates such as weight, age, sex, ethnic origin, etc. Genetic polymorphisms susceptible to modify pharmacokinetic or pharmacodynamic parameters are much harder to include, especially as there are millions of possible polymorphisms (and thus covariates) per patient.

The challenge is to determine which genetic covariates are associated to some PKPD parameters and/or implicated in patient responses to a given drug.

Another problem encountered is the dependence of genes, as indeed, gene expression is a highly regulated process. In cases where the explanatory variables (genomic variants) are correlated, Lasso-type methods for model selection are thwarted.

There is therefore a clear need for new methods and algorithms for the estimation, validation and selection of mixed effects models adapted to the problems of genomic medicine.

A target application of this project concerns the lung cancer.

EGFR (Epidermal Growth Factor Receptor) is a cell surface protein that binds to epidermal growth factor. We know that deregulation of the downstream signaling pathway of EGFR is involved in the development of lung cancers and several gene mutations responsible for this deregulation are known.

Our objective is to identify the variants responsible for the disruption of this pathway using a modeling approach. The data that should be available for developing such model are ERK (Extracellular signal–regulated kinases) phosphorylation time series, obtained from different genetic profiles.

The model that we aim to develop will describe the relationship between the parameters of the pathway and the genomic covariates, i.e. the genetic profile. Variants related to the pathway include: variants that modify the affinity binding of ligands to receptors, variants that modify the total amount of protein, variants that affect the catalytic site,…

### 4.3 Oncology

(joint project with the Biochemistry lab of Ecole Polytechnique and Institut Curie)

In cancer, the most dreadful event is the formation of metastases that disseminate tumor cells throughout the organism. Cutaneous melanoma is a cancer, where the primary tumor can easily be removed by surgery. However, this cancer is of poor prognosis; because melanomas metastasize often and rapidly. Many melanomas arise from excessive exposure to mutagenic UV from the sun or sunbeds. As a consequence, the mutational burden of melanomas is generally high.

RAC1 encodes a small GTPase that induces cell cycle progression and migration of melanoblasts during embryonic development. Patients with the recurrent P29S mutation of RAC1 have 3-fold increased odds at having regional lymph nodes invaded at the time of diagnosis. RAC1 is unlikely to be a good therapeutic target, since a potential inhibitor that would block its catalytic activity, would also lock it into the active GTP-bound state. This project thus investigates the possibility of targeting the signaling pathway downstream of RAC1.

**XPOP** is mainly involved in Task 1 of the project: *Identifying deregulations and mutations of the ARP2/3 pathway in melanoma patients.*

Association of over-expression or down-regulation of each marker with poor prognosis in terms of invasion of regional lymph nodes, metastases and survival, will be examined using classical univariate and multivariate analysis. We will then develop specific statistical models for survival analysis in order to associate prognosis factors to each composition of complexes. Indeed, one has to implement the further constraint that each subunit has to be contributed by one of several paralogous subunits. An original method previously developed by **XPOP** has already been successfully applied to WAVE complex data in breast cancer.

The developed models will be rendered user-friendly though a dedicated Rsoftware package.

This project can represent a significant step forward in precision medicine of the cutaneous melanoma.

### 4.4 Anesthesiology

(joint project with AP-HP Lariboisière and M3DISIM)
Two hundred million general anaesthesias are performed worldwide every year. Low blood pressure during anaesthesia is common and has been identified as a major factor in morbidity and mortality. These events require great reactivity in order to correct them as quickly as possible and impose constraints of reliability and reactivity to monitoring and treatment.

Recently, studies have demonstrated the usefulness of noradrenaline in preventing and treating intraoperative hypotension. The handling of this drug requires great vigilance with regard to the correct dosage. Currently, these drugs are administered manually by the healthcare staff in bolus and/or continuous infusion. This represents a heavy workload and suffers from a great deal of variability in order to find the right dosage for the desired effect on blood pressure.

The objective of this project is to automate the administration of noradrenaline with a closed-loop system that makes it possible to control the treatment in real time to an instantaneous blood pressure measurement.

4.5 Intracellular processes
(joint project with the InBio and IBIS inria teams and the MSC lab, UMR 7057)

Significant cell-to-cell heterogeneity is ubiquitously-observed in isogenic cell populations. Cells respond differently to a same stimulation. For example, accounting for such heterogeneity is essential to quantitatively understand why some bacteria survive antibiotic treatments, some cancer cells escape drug-induced suicide, stem cell do not differentiate, or some cells are not infected by pathogens.

The origins of the variability of biological processes and phenotypes are multifarious. Indeed, the observed heterogeneity of cell responses to a common stimulus can originate from differences in cell phenotypes (age, cell size, ribosome and transcription factor concentrations, etc), from spatio-temporal variations of the cell environments and from the intrinsic randomness of biochemical reactions. From systems and synthetic biology perspectives, understanding the exact contributions of these different sources of heterogeneity on the variability of cell responses is a central question.

The main ambition of this project is to propose a paradigm change in the quantitative modelling of cellular processes by shifting from mean-cell models to single-cell and population models. The main contribution of XPOP focuses on methodological developments for mixed-effects model identification in the context of growing cell populations.

- Mixed-effects models usually consider an homogeneous population of independent individuals. This assumption does not hold when the population of cells (i.e. the statistical individuals) consists of several generations of dividing cells. We then need to account for inheritance of single-cell parameters in this population. More precisely, the problem is to attribute the new state and parameter values to newborn cells given (the current estimated values for) the mother.

- The mixed-effects modelling framework corresponds to a strong assumption: differences between cells are static in time (i.e, cell-specific parameters have fixed values). However, it is likely that for any given cell, ribosome levels slowly vary across time, since like any other protein, ribosomes are produced in a stochastic manner. We will therefore extend our modelling framework so as to account for the possible random fluctuations of parameter values in individual cells. Extensions based on stochastic differential equations will be investigated.

- Identifiability is a fundamental prerequisite for model identification and is also closely connected to optimal experimental design. We will derive criteria for theoretical identifiability, in which different parameter values lead to non-identical probability distributions, and for structural identifiability, which concerns the algebraic properties of the structural model, i.e. the ODE system. We will then address the problem of practical identifiability, whereby the model may be theoretically identifiable but the design of the experiment may make parameter estimation difficult and imprecise. An interesting problem is whether accounting for lineage effects can help practical identifiability of the parameters of the individuals in presence of measurement and biological noise.

4.6 Population pharmacometrics
(joint project with Lixoft)
Pharmacometrics involves the analysis and interpretation of data produced in pre-clinical and clinical trials. Population pharmacokinetics studies the variability in drug exposure for clinically safe and effective doses by focusing on identification of patient characteristics which significantly affect or are highly correlated with this variability. Disease progress modeling uses mathematical models to describe, explain, investigate and predict the changes in disease status as a function of time. A disease progress model incorporates functions describing natural disease progression and drug action.

The model based drug development (MBDD) approach establishes quantitative targets for each development step and optimizes the design of each study to meet the target. Optimizing study design requires simulations, which in turn require models. In order to arrive at a meaningful design, mechanisms need to be understood and correctly represented in the mathematical model. Furthermore, the model has to be predictive for future studies. This requirement precludes all purely empirical modeling; instead, models have to be mechanistic.

In particular, physiologically based pharmacokinetic models attempt to mathematically transcribe anatomical, physiological, physical, and chemical descriptions of phenomena involved in the ADME (Absorption - Distribution - Metabolism - Elimination) processes. A system of ordinary differential equations for the quantity of substance in each compartment involves parameters representing blood flow, pulmonary ventilation rate, organ volume, etc.

The ability to describe variability in pharmacometrics model is essential. The nonlinear mixed-effects modeling approach does this by combining the structural model component (the ODE system) with a statistical model, describing the distribution of the parameters between subjects and within subjects, as well as quantifying the unexplained or residual variability within subjects.

The objective of XPOP is to develop new methods for models defined by a very large ODE system, a large number of parameters and a large number of covariates. Contributions of XPOP in this domain are mainly methodological and there is no privileged therapeutic application at this stage. However, it is expected that these new methods will be implemented in software tools, including MONOLIX and Rpackages for practical use.

4.7 Mass spectrometry
(joint project with the Molecular Chemistry Laboratory, LCM, of Ecole Polytechnique)

One of the main recent developments in analytical chemistry is the rapid democratization of high-resolution mass spectrometers. These instruments produce extremely complex mass spectra, which can include several hundred thousand ions when analyzing complex samples. The analysis of complex matrices (biological, agri-food, cosmetic, pharmaceutical, environmental, etc.) is precisely one of the major analytical challenges of this new century. Academic and industrial researchers are particularly interested in trying to quickly and effectively establish the chemical consequences of an event on a complex matrix. This may include, for example, searching for pesticide degradation products and metabolites in fruits and vegetables, photoproducts of active ingredients in a cosmetic emulsion exposed to UV rays or chlorination products of biocides in hospital effluents. The main difficulty of this type of analysis is based on the high spatial and temporal variability of the samples, which is in addition to the experimental uncertainties inherent in any measurement and requires a large number of samples and analyses to be carried out and computerized data processing (up to 16 million per mass spectrum).

A collaboration between XPOP and the Molecular Chemistry Laboratory (LCM) of the Ecole Polytechnique began in 2018. Our objective is to develop new methods for the statistical analysis of mass spectrometry data.

These methods are implemented in the SPIX software.

5 Highlights of the year

5.1 Awards

The Technical Achievement Award for 2020 is awarded to Eric Moulines, for major contributions in statistical inference, in particular in hidden Markov chains and non-linear state models.
5.2 Other

Created to address technological developments and data issues in the medical field, the “Numerical Innovation and Data Science for Healthcare” sponsorship program with Ecole polytechnique and Sanofi was inaugurated on November 13th. Marc Lavielle is co-leader of this program.

6 New software and platforms

6.1 New software

6.1.1 mlxR

Keywords: Simulation, Data visualization, Clinical trial simulator

Functional Description: The models are encoded using the model coding language 'Mlxtran', automatically converted into C++ codes, compiled on the fly and linked to R using the 'Rcpp' package. That allows one to implement very easily complex ODE-based models and complex statistical models, including mixed effects models, for continuous, count, categorical, and time-to-event data.

URL: [http://simulx.webpopix.org/](http://simulx.webpopix.org/)

Contact: Marc Lavielle

6.1.2 Rsmlx

Name: R speaks Monolix

Keywords: Data modeling, Nonlinear mixed effects models, Statistical modeling

Functional Description: Among other tasks, 'Rsmlx' provides a powerful tool for automatic PK model building, performs statistical tests for model assessment, bootstrap simulation and likelihood profiling for computing confidence intervals. 'Rsmlx' also proposes several automatic covariate search methods for mixed effects models.

URL: [http://rsmlx.webpopix.org/](http://rsmlx.webpopix.org/)

Contact: Marc Lavielle

Partner: Lixoft

6.1.3 SPIX

Keywords: Data modeling, Mass spectrometry, Chemistry

Functional Description: SPIX allows you to - automatically identify, on the basis of statistical approaches, small but significant differences in spectra measured under different conditions, - model the kinetics of entities that evolve over time

URL: [http://spix.webpopix.org/](http://spix.webpopix.org/)

Authors: Marc Lavielle, Yao Xu

Contact: Marc Lavielle

Partner: Laboratoire de Chimie Moléculaire - Ecole Polytechnique
7 New results

7.1 Fast incremental expectation-maximization algorithm

Fast Incremental Expectation Maximization (FIEM) is an iterative algorithm, based on the Expectation Maximization (EM) algorithm, which was introduced to design EM for the large scale learning framework by avoiding the full data set to be processed at each iteration. In this paper, we first recast this algorithm in the Stochastic Approximation (SA) within EM framework. Then, we provide non asymptotic convergence rates as a function of the batch size $n$ and of the maximal number of iterations $K_{max}$ fixed by the user.

7.2 A mathematical approach to deal with nanoparticle polydispersity in surface enhanced Raman spectroscopy to quantify antineoplastic agents

Antineoplastic agents are, for most of them, highly toxic drugs prepared at hospital following individualized prescription. To protect patients and healthcare workers, it is important to develop analytical tools able to identify and quantify such drugs on a wide concentration range. In this context, surface enhanced Raman spectroscopy (SERS) has been tested as a specific and sensitive technique. Despite the standardization of the nanoparticle synthesis, a polydispersity of nanoparticles in the suspension and a lack of reproducibility persist. This study focuses on the development of a new mathematical approach to deal with this nanoparticle polydispersity and its consequences on SERS signal variability through the feasibility of 5-fluorouracil (5FU) quantification using silver nanoparticles (AgNPs) and a handled Raman spectrophotometer. Variability has been maximized by synthesizing six different batches of AgNPs for an average size of 24.9 nm determined by transmission electron microscopy, with residual standard deviation of 17.0%. Regarding low performances of the standard multivariate data processing, an alternative approach based on the nearest neighbors were developed to quantify 5FU. By this approach, the predictive performance of the 5FU concentration was significantly improved. The mean absolute relative error (MARE) decreased from 16.8% with the traditional approach based on PLS regression to 6.30% with the nearest neighbors approach (p-value < 0.001). This study highlights the importance of developing mathematics adapted to SERS analysis which could be a step to overcome the spectral variability in SERS and thus participate in the development of this technique as an analytical tool in quality control to quantify molecules with good performances, particularly in the pharmaceutical field [6].

7.3 Doubly robust treatment effect estimation with missing attributes

Missing attributes are ubiquitous in causal inference, as they are in most applied statistical work. In this paper, we consider various sets of assumptions under which causal inference is possible despite missing attributes and discuss corresponding approaches to average treatment effect estimation, including generalized propensity score methods and multiple imputation. Across an extensive simulation study, we show that no single method systematically out-performs others. We find, however, that doubly robust modifications of standard methods for average treatment effect estimation with missing data repeatedly perform better than their non-doubly robust baselines; for example, doubly robust generalized propensity score methods beat inverse-weighting with the generalized propensity score. This finding is reinforced in an analysis of an observations study on the effect on mortality of tranexamic acid administration among patients with traumatic brain injury in the context of critical care management. Here, doubly robust estimators recover confidence intervals that are consistent with evidence from randomized trials, whereas non-doubly robust estimators do not [9].

7.4 Imputation and low-rank estimation with Missing Non At Random data

Missing values challenge data analysis because many supervised and unsupervised learning methods cannot be applied directly to incomplete data. Matrix completion based on low-rank assumptions are very powerful solution for dealing with missing values. However, existing methods do not consider the case of informative missing values which are widely encountered in practice. We propose matrix completion methods to recover Missing Not At Random (MNAR) data. Our first contribution is to suggest a model-based estimation strategy by modelling the missing mechanism distribution. An EM algorithm is then
implemented, involving a Fast Iterative Soft-Thresholding Algorithm (FISTA). Our second contribution is to suggest a computationally efficient surrogate estimation by implicitly taking into account the joint distribution of the data and the missing mechanism: the data matrix is concatenated with the mask coding for the missing values; a low-rank structure for exponential family is assumed on this new matrix, in order to encode links between variables and missing mechanisms. The methodology that has the great advantage of handling different missing value mechanisms is robust to model specification errors [11].

7.5 On Stability of a Class of Filters for Nonlinear Stochastic Systems

We developed a comprehensive framework for stability analysis of a broad class of commonly used continuous-and discrete-time filters for stochastic dynamic systems with nonlinear state dynamics and linear measurements under certain strong assumptions. The class of filters encompasses the extended and unscented Kalman filters and most other Gaussian assumed density filters and their numerical integration approximations. The stability results are in the form of time-uniform mean square bounds and exponential concentration inequalities for the filtering error. In contrast to existing results, it is not always necessary for the model to be exponentially stable or fully observed. We review three classes of models that can be rigorously shown to satisfy the stringent assumptions of the stability theorems. Numerical experiments using synthetic data validate the derived error bounds. [7].

7.6 SPIX: a new software package to reveal chemical reactions at trace amounts in very complex mixtures from high-resolution mass spectra data sets

High-resolution mass spectrometry-based non-targeted screening has a huge potential for applications in environmental sciences, engineering and regulation. However, it produces big data for which full appropriate processing is a real challenge; the development of processing software is the last building-block to enable large-scale use of this approach. Methods: A new software application, SPIX, has been developed to extract relevant information from high-resolution mass-spectrum datasets. Dealing with intrinsic sample variability and reducing operator subjectivity, it opens up opportunities and promising prospects in many areas of analytical chemistry.

Two features of the software are presented in the field of environmental analysis. An example illustrates how SPIX reveals photodegradation reactions in wastewater by fitting kinetic models to significant changes in ion abundance over time. A second example shows the ability of SPIX to detect photoproducts at trace amounts in river water, through comparison of datasets from samples taken before and after irradiation. Conclusions: SPIX has shown its ability to reveal relevant modifications between two series of big data sets, allowing for instance to study the consequences of a given event on a complex substrate. Most of all and this is to our knowledge the only software currently available allowing that it can reveal and monitor any kind of reaction in all types of mixture [10].

8 Partnerships and cooperations

8.1 National initiatives

8.1.1 ANR

*Mixed-Effects Models of Intracellular Processes: Methods, Tools and Applications (MEMIP)*

Coordinator: Gregory Batt (InBio Inria team)

Other partners: InBio and IBIS Inria teams, Laboratoire Matière et Systèmes Complexes (UMR 7057; CNRS and Paris Diderot Univ.)

8.1.2 Institut National du Cancer (INCa)

*Targeting Rac-dependent actin polymerization in cutaneous melanoma - Institut National du Cancer*

Coordinator: Alexis Gautreau (Ecole Polytechnique)

Other partners: Laboratoire de Biochimie (Polytechnique), Institut Curie, INSERM.
9 Dissemination

9.1 Promoting scientific activities

9.1.1 Journal

Member of the editorial boards

- Stochastic Processes and their Applications
- Journal of Statistical Planning and Inference
- Journal of Computational and Graphical Statistics

Reviewer - reviewing activities diverse and varied

9.1.2 Leadership within the scientific community

- Eric Moulines is in charge of the academic supervision of the International Laboratory of Stochastic Algorithms and High-dimensional inference, National Research University, Higher School of Economics, funded by the Russian Academic Excellence Project.
- Eric Moulines is is associate researcher of the Alan Turing Institute
- Eric Moulines is elected member of the French Académie des Sciences.
- Julie Josse is visiting researcher at Google France

9.1.3 Scientific expertise

- Marc Lavielle is member of the Scientific Committee of the High Council for Biotechnologies.
- Marc Lavielle is member of the evaluation committee of the International Center for Mathematics (CIMAT), Guanajuato, Mexico.
- Eric Moulines is member of the award committee of foundation "Charles Defforey".

9.1.4 Research administration

- Marc Lavielle is member of the Scientific Programming Committee (CPS) of the Institute Henri Poincaré (IHP).
- Julie Josse is elected member of the R foundation.

9.2 Teaching - Supervision - Juries

9.2.1 Teaching

- Master : Julie Josse, Statistics with R, 48, M2, X-HEC
- Master : Eric Moulines, Regression models, 36, M2, X-HEC
- Engineering School : Eric Moulines, Markov Chains, 36, 3A, X
- Engineering School : Erwan Le Pennec, Statistical Learning, 36, 3A, X
- Engineering School : Marc Lavielle, Statistics in Action, 48, 3A, X
9.2.2 Supervision

- PhD defended: Marine Zulian, February 2020, Marc Lavielle
- PhD defended: Wei Jiang, September 2020, Julie Josse and Marc Lavielle
- PhD in progress: Achille Thin, October 2020, Eric Moulines
- PhD in progress: Pablo Jimenez, October 2020, Eric Moulines

9.3 Popularization

9.3.1 Education

Marc Lavielle developed and maintains the learning platform Statistics in Action. The purpose of this online learning platform is to show how statistics (and biostatistics) may be efficiently used in practice using R. It is specifically geared towards teaching statistical modelling concepts and applications for self-study. Indeed, most of the available teaching material tends to be quite "static" while statistical modelling is very much subject to "learning by doing".

Julie Josse (with Nicholas Tierney and Nathalie Vialaneix) developed and maintains the website R-miss-tastic, A resource website on missing data.

9.3.2 Interventions

10 Scientific production

10.1 Major publications


10.2 Publications of the year

International journals


**International peer-reviewed conferences**


**Conferences without proceedings**


**Reports & preprints**

Avis en réponse à la saisine du 2 juillet 2020 relative au projet de décret modifiant l'article D.531-2 du code de l'environnement. Haut Conseil des Biotechnologies, 2020, 44 p. URL: https://hal.inrae.fr/hal-02917686.


Alternative subgroup joint analysis proposal of nonlinear longitudinal and time-to-event data for modeling pregnancy miscarriage. 29th Nov. 2020. URL: https://hal.archives-ouvertes.fr/hal-03029909.

Convergence Analysis of Riemannian Stochastic Approximation Schemes. 27th May 2020. URL: https://hal.archives-ouvertes.fr/hal-02626383.

Fast Incremental Expectation Maximization for finite-sum optimization: nonasymptotic convergence. 21st Dec. 2020. URL: https://hal.archives-ouvertes.fr/hal-02617725.


Adaptive Bayesian SLOPE—High-dimensional Model Selection with Missing Values. 7th Jan. 2020. URL: https://hal.archives-ouvertes.fr/hal-02430600.

On the consistency of supervised learning with missing values. 29th June 2020. URL: https://hal.archives-ouvertes.fr/hal-02024202.

Extension of a SIR model for modelling the propagation of Covid-19 in several countries. 9th Nov. 2020. DOI: 10.1101/2020.05.17.20104885. URL: https://hal.archives-ouvertes.fr/hal-02995305.


CYFIP2 containing WAVE complexes inhibit cell migration. 25th Nov. 2020. DOI: 10.1101/2020.07.02.184655. URL: https://hal.archives-ouvertes.fr/hal-03014297.

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalised for COVID-19 infection: a cohort study of 4,642 in-patients in France. 9th Nov. 2020. DOI: 10.1101/2020.06.16.20132597. URL: https://hal.archives-ouvertes.fr/hal-02995319.

**Other scientific publications**